Fig. 2From: Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochlorideFTIR spectra of duloxetine HCl (a); HPMC (K15 CR) (b); formulation with HPMC (K15 CR) (c); and physical mixture of DLX and HPMC (K15 CR) (d)Back to article page